Biomarker ID | 1415 |
PMID | 24741114 |
Year | 2014 |
Biomarker | TIMP1; CLUS; MFAP4; AOC3; CADM1; HYOU1; FSTL1; KLK11; NBL1; GOLM1; VTNC; CERU; A1AG2; LYVE1; A1AG1; |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Metastatic PCa;Downregulated in Non Metastatic PCa: [] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Metastatic Vs Non Metastatic Prostate Cancer |
Type of Biomarker | Prognostic |
Cohort | 25 patients with Metastatic Prostate Cancer (PCa); 10 normal samples; 24 Non Agressive PCa patients and 16 agressive PCa patients were included in the study |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | NA |
Method Used | SWATH Mass Spectrometry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |